Bristol-Myers Can't Dodge Celgene Investors' Drug Delay Suit

By Craig Clough · June 24, 2022, 10:16 PM EDT

UMB Bank can pursue its claims that Bristol-Myers Squibb improperly delayed U.S. Food and Drug Administration approval of a cancer treatment to avoid paying $6.4 billion owed from a 2019 acquisition...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

UMB Bank, N.A. v. Bristol-Myers Squibb Company

Case Number

Court

New York Southern

Nature of Suit

Contract: Other

Date Filed

June 02, 2021

Recent Articles By Craig

August 30, 2024
Doctor In Matthew Perry's Death Makes 1st Court Appearance
August 16, 2024
Baltimore Inks $152.5M Opioid Deal With Cardinal Health
July 08, 2024
Patient Says Health System Shares Data With Meta, Google
May 31, 2024
9th Circ. Affirms Toss Of Health Center's $8M Cigna Row
May 23, 2024
Charges Tossed For Army Doc, Wife In Russia Data Leak Case
May 23, 2024
LA Jury Awards $58M To Train Yard Worker Injured In Slip
April 30, 2024
Judge Strikes Parts Of NC Law Restricting Abortion Drug
April 29, 2024
9th Circ. Scraps Trans Law Opinion After High Court Ruling
April 10, 2024
DOJ Hits Regeneron With False Claims Act Suit Over Eylea
March 07, 2024
Netflix, Privacy Plaintiffs Scolded For 'Entirely Deficient' Filing